145 results
8-K
EX-99.1
LUMO
Lumos Pharma Inc
5 Jun 24
Lumos Pharma Announces New Analyses of Phase 2
4:09pm
3 trial, as well as advance our clinical and corporate strategy in general, our ability to project future cash utilization and reserves needed
8-K
EX-99.2
LUMO
Lumos Pharma Inc
5 Jun 24
Lumos Pharma Announces New Analyses of Phase 2
4:09pm
3 program Initiation of Phase 3 trial anticipated Q4 2024 PEM strategy de-risks patient selection, identifying likely LUM-201 responders*** Phase 2 … Market conducted for Lumos by Triangle Insights *** PEM (Predictive Enrichment Marker) investigational strategy consists of screening for PEM-positive
8-K
EX-99.2
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
trial anticipated Q4 2024 PEM strategy de-risks patient selection, identifying likely LUM-201 responders** Phase 2 trials met all primary … Insights *** PEM (Predictive Enrichment Marker) strategy consists of screening for PEM+ PGHD patients = Baseline IGF-1 30 ng/ml & Peak stimulation GH
8-K
EX-99.2
rd9 ymz5s
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
EX-99.1
6b7 hxc8zi
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
EX-99.1
h2f3hn
4 Jan 24
Regulation FD Disclosure
4:34pm
8-K
EX-99.1
48a8ifkv28ypwl
15 Nov 23
Other Events
4:38pm
8-K
EX-99.1
ziq0o bt9eo
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
EX-99.2
2pcfl9274km
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.1
ceew8x7n4
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.1
v0k8u8ib0mku3568i
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.2
yiy re45bvp
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.2
u7qczct
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
EX-99.1
60rwbq
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm